欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (6): 686-689.

• 基础研究 • 上一篇    下一篇

2, 3-二氢-7-甲氧基-4h-1-苯并吡喃-4-异烟腙抗骨质疏松作用的体外活性研究

王捷频1,3, 尚福军2, 熊晓云1, 刘莉1, 侯进1, 梅其炳1   

  1. 1第四军医大学药学系药理教研室, 西安710032, 陕西;
    2第四军医大学唐都医院心内科, 西安710038, 陕西;
    3第四军医大学药学系药物研究所, 西安710032, 陕西
  • 收稿日期:2007-03-01 修回日期:2007-04-25 发布日期:2020-11-09
  • 通讯作者: 梅其炳, 男, 教授, 博士生导师, 从事药理学研究。Tel Fax: 029-84774552 E-mail:pharm-mei@hotmail.com
  • 作者简介:王捷频, 女, 博士, 药师, 现从事骨质疏松研究。Tel:029-84774555 E-mail:wangjp @fmmu. edu. cn

Study on anti-osteoporosis bioactivity of 2, 3-dihydro-7-methoxy-4h-1-benzopyran-4-isoniazonum in vitro

WANG Jie-pin1,3, SHANG Fu-jun2, XIONG Xiao-yun1, LIU Li1, HOU Jin1, MEI Qi-bing1   

  1. 1Department of Pharmacology, School of Pharmacy, Fourth Millitary Medical University, Xi ' an 710032, Shaanxi,China;
    2Department of Cardiology, Tangdu Hospital, Fourth Millitary Medical University, Xi ' an 710038, Shaanxi,China;
    3Institute of Materia Medica, School of Pharmacy, Fourth Millitary Medical University, Xi ' an 710032,Shaanxi, China
  • Received:2007-03-01 Revised:2007-04-25 Published:2020-11-09

摘要: 目的:在已有的研究基础上, 从我们合成的一系列化合物中筛选出具有抗骨质疏松活性的化合物I(2, 3-二氢-7-甲氧基-4h-1-苯并吡喃-4-异烟腙), 对其体外活性进行研究。方法:以雌二醇(E2) 作为阳性对照, 以细胞增殖作用、碱性磷酸酶(ALP) 活性和骨钙素(OCN) 分泌为指标考察该化合物对成骨细胞系MC3T3-E1 细胞的增殖和分化的影响。结果:化合物I 在10-6 mol/L浓度时对体外培养的细胞有较好的促进作用, 显著增加细胞数量(125. 73%, 与对照组比较P<0. 05), 提高ALP 活性(108. 49%, 与对照组比较P<0. 05), 且能够促进骨钙素分泌(109. 00%, 与对照组比较P<0. 05), 以上作用均可被雌激素受体(ER) 阻断剂tamoxifen 阻断。结论:化合物I 具有促进成骨细胞增殖分化的作用, 其机制可能与ER 激动有关。

关键词: MC3T3-E1 细胞, MTT, 碱性磷酸酶活性, 骨钙素分泌

Abstract: AIM:From early studies an anti-osteoporosis compound I (2, 3-dihydro-7-methoxy-4h-1-benzopyran-4-isoniazonum) was screened and here to discuss its bioactivity in vitro.METHODS: Compared with estrodiol (E2), the cell proliferation, alkaline phosphatase (ALP) activity and osteocalcin (OCN) secretion as indexes to determine the effects of this compound on proliferation and differentiation of osteoblast cell line MC3T3-E1.RESULTS:The best dose of compound I was 10-6 mol/L. At this concentration, compound I could significantly increase the number of osteoblast cells, elevate ALP activity and OCN secretion (125. 73%, 108. 49% 109. 00% vs control, P<0. 05). All these effects could be blocked by introducing of the antieatrogen tamoxifen.CONCLUSION:Compound I has the ability in treating osteoporosis, whose mechanism maybe relate to estrogen agonist.

Key words: MC3T3-E1 cells, MTT, alkaline phosphatase activities, osteocalcin secretion

中图分类号: